Drug Shortage Report for TAKHZYRO

Last updated on 2022-01-13 History
Report ID 151175
Drug Identification Number 02480948
Brand name TAKHZYRO
Common or Proper name Lanadelumab Injection
Company Name TAKEDA CANADA INC
Market Status MARKETED
Active Ingredient(s) LANADELUMAB
Strength(s) 300MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 2 mL Vial
ATC code B06AC
ATC description
Reason for shortage Delay in shipping of the drug.
Anticipated start date 2021-12-15
Actual start date 2021-12-15
Estimated end date 2022-01-14
Actual end date 2022-01-12
Shortage status Resolved
Updated date 2022-01-13
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 22 ADELAIDE STREET WEST
TORONTO, ONTARIO
CANADA M5H 4E3
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v8 2022-01-13 French Compare
v7 2022-01-13 English Compare
v6 2022-01-06 French Compare
v5 2022-01-06 English Compare
v4 2021-12-16 English Compare
v3 2021-12-15 French Compare
v2 2021-12-15 English Compare
v1 2021-12-15 English Compare

Showing 1 to 8 of 8